Could Targeting miRNA-142-5p Be a Therapeutic Strategy Against COVID-19 Through Activation of The Anti-Inflammatory Nrf2/Keap1 Pathway?
Last updated: 03 Jan 2025
10.21608/eajbsc.2022.225920
respiratory distress, COVID-19, miRNA-142-5p, Nrf2, Keap1
Engy
Medhat
The Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Egypt.
Mai
Samir
The Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Egypt.
Riem
Elmessiery
M.
The Department of Internal Medicine, Faculty of Medicine, Cairo University, Egypt.
reimelmessiery@kasralainy.edu.com
Shimaa
El-Din
Saad
The Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Egypt.
shimaasaadaldin@yahoo.com
Cairo
14
1
29927
2022-06-01
2022-03-02
2022-06-01
175
186
2090-0767
2090-083X
https://eajbsc.journals.ekb.eg/article_225920.html
https://eajbsc.journals.ekb.eg/service?article_code=225920
16
Original Article
673
Journal
Egyptian Academic Journal of Biological Sciences. C, Physiology and Molecular Biology
https://eajbsc.journals.ekb.eg/
Could Targeting miRNA-142-5p Be a Therapeutic Strategy Against COVID-19 Through Activation of The Anti-Inflammatory Nrf2/Keap1 Pathway?
Details
Type
Article
Created At
22 Jan 2023